8-K: Dynavax Responds to Deep Track's Board Nomination, Highlights Long-Term Value Strategy

Dynavax addresses Deep Track Capital's nomination of board candidates, emphasizing its commitment to long-term stockholder value and defending its strategic plan.

Summary

• Dynavax Technologies Corporation has responded to Deep Track Capital's nomination of four candidates for election to the company's Board of Directors at the 2025 Annual Meeting of Stockholders.
• Dynavax underscores its commitment to driving long-term stockholder value through a strategic plan focused on strong financial results and sustainable growth.
• The company highlights its track record of strong financial performance, underpinned by disciplined and balanced capital allocation.
• Key priorities include driving growth of HEPLISAV-B, advancing a differentiated vaccine pipeline, and maintaining a disciplined approach to capital allocation.
• HEPLISAV-B achieved record annual revenue in 2024, with 26% year-over-year growth, positioning Dynavax at the upper tier of its updated guidance range.
• Dynavax expects to achieve at least 60% total market share for HEPLISAV-B by 2030.
• The company is advancing a novel shingles vaccine program and has secured a new $30 million contract with the U.S. Department of Defense to advance its plague vaccine program.
• Dynavax's balance sheet shows $714 million in cash as of year-end 2024, enabling the company to pursue pipeline development and external opportunities.
• In November 2024, Dynavax announced a $200 million share repurchase plan, with $100 million executed through an accelerated share repurchase program.
• The company discontinued its Tdap program in the third quarter of 2024 due to unsatisfactory study results.
• The Board initiated a refreshment program in August 2024, appointing two new independent directors and planning for two current directors to step down at the 2025 Annual Meeting.
• The Board intends to seek stockholder approval at the 2025 Annual Meeting for the declassification of the Board.
• Dynavax states that Deep Track's proposed strategy is flawed and value-destructive, involving abandoning portfolio diversification, returning cash needed for growth, and selling Dynavax as a single-asset company.
• The Board has engaged with Deep Track but rejected their demands for control of the Board without paying a control premium.
• Dynavax remains committed to constructive engagement with Deep Track while protecting the best interests of all stockholders.
• The Board will review Deep Track's materials and present its formal recommendation regarding director nominations in its proxy statement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company highlights its achievements and defends its strategy, the proxy contest introduces uncertainty and potential disruption.

Positives

• Strong HEPLISAV-B revenue growth of 26% year-over-year in 2024.
• Expectation of achieving at least 60% market share for HEPLISAV-B by 2030.
• New $30 million contract with the U.S. Department of Defense for plague vaccine program.
• Strong cash position of $714 million as of year-end 2024.
• $200 million share repurchase program to return excess cash to stockholders.
• Board refreshment program with the appointment of two new independent directors.
• Planned declassification of the Board to improve corporate governance.

Negatives

• Deep Track Capital's attempt to gain control of the Board without paying a control premium.
• Deep Track's proposed strategy is considered value-destructive by Dynavax management.
• Potential distraction and cost associated with a proxy contest.
• Discontinuation of the Tdap program due to unsatisfactory study results.

Risks

• The risk that circumstances surrounding or leading up to the 2025 Annual Meeting may change.
• Risks relating to the company's ability to commercialize and supply HEPLISAV-B.
• Risks related to the implementation of the company's long-term growth objectives.
• Potential disruption from a proxy contest initiated by Deep Track Capital.

Future Outlook

Dynavax expects to achieve at least 60% total market share for HEPLISAV-B by 2030 and is focused on advancing its vaccine pipeline and pursuing external opportunities to expand its portfolio.

Management Comments

• Dynavax has been successfully executing a clear strategic plan focused on three core priorities which is consistently delivering strong financial results and sustainable long-term value.
• Deep Tracks strip-mining plan for Dynavax jeopardizes a strong platform with significant long-term growth opportunities for a near-term payoff of a considerably lower value.
• The Board believes this proxy contest is unreasonable and disregards multiple constructive settlement offers by the Board, Dynavax remains committed to constructive and reasonable engagement with Deep Track, while ensuring that the best interests of all stockholders not only those of Mr. Kroin and his fund are protected and represented.

Industry Context

The announcement comes as Dynavax faces pressure from an activist investor, Deep Track Capital, highlighting the ongoing scrutiny and potential for strategic shifts in the biopharmaceutical industry. The focus on HEPLISAV-B's market share and the development of a shingles vaccine places Dynavax in competition with major players in the vaccine market.

Comparison to Industry Standards

• Dynavax's HEPLISAV-B competes with GSK's Shingrix in the adult vaccination market; achieving 60% market share by 2030 would position it as a significant player.
• The $30 million contract with the U.S. Department of Defense is comparable to other government contracts awarded to biopharmaceutical companies for vaccine development.
• The $200 million share repurchase program is a common capital allocation strategy among publicly traded companies with strong cash positions, similar to programs implemented by companies like Amgen and Gilead.

Management Changes

Corporate Governance

Stakeholder Impact

• Stockholders: Potential impact on stock value and company strategy depending on the outcome of the proxy contest.
• Employees: Potential uncertainty and disruption due to the proxy contest and potential changes in company strategy.
• Customers: No immediate impact expected, but long-term strategy changes could affect product development and availability.

Next Steps

• The Board will review Deep Track's materials and present its formal recommendation regarding director nominations in its proxy statement.
• Dynavax will file a proxy statement with the SEC in connection with the solicitation of proxies for the 2025 Annual Meeting.
• Stockholders will vote on director nominations and a proposal to declassify the Board at the 2025 Annual Meeting.

Key Dates